When was Biopure founded?

Biopure was founded in 1984 and raised its 1st funding round 13 years after it was founded.

Where is Biopure located?

Biopure is headquartered in United States.

Is Biopure a funded company?

Biopure is a funded company, having raised a total of $51.6M across 8 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Dec 02, 1997.

When was the latest funding round of Biopure?

Biopure's latest funding was a $***** Post IPO round on Nov 06, 2013, with participation from 1 investor.

Where does Biopure rank among its competitors?

Biopure ranks 16th amongst 29 active competitors, of which 5 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Editas Medicine, which secured $2M in Dec, 2023.

Who are the top competitors of Biopure?

Biopure's top competitors include Editas Medicine, LogicBio and Kedrion. Among them, Editas Medicine secured the most recent funding round in December, 2023.

Biopure - 2026 Company Profile, Team, Funding & Competitors

Biopure is a deadpooled company based in United States, founded in 1984. It operates as a Mold remediation, water damage restoration, and infectious disease control services. Biopure has raised $51.6M in funding. The company has 29 active competitors, including 5 funded and 11 that have exited. Its top competitors include companies like Editas Medicine, LogicBio and Kedrion.

Company Details

Mold remediation, water damage restoration, and infectious disease control services. This company offers turnkey solutions for environmental remediation and construction, focusing on innovation, quality control, and sustainability. They provide services such as water extraction, rapid drying, mold remediation, construction site services, infectious disease control, and fire & smoke restoration. Their proprietary technology, PureZyme, is a non-toxic antimicrobial solution effective against germs, viruses, bacteria, and mold. They cater to property managers, developers, builders, insurance carriers, government contracts, and property owners, offering solutions for water mitigation, mold remediation, and contaminant removal. They are a service-disabled veteran-owned small business, partnering with government entities to provide environmental and germ control solutions. Their services extend to offices, schools, gyms, and other facilities, ensuring cleaner and safer environments.

Key Metrics

Founded Year

1984

Location

United States

Stage

Deadpooled

Total Funding

$51.6M in 8 rounds

Latest Funding Round

Post IPO, Nov 06, 2013, $*****

Investors

Oaktree Capital Management & 5 more

Ranked

16^th among 29 active competitors

Similar Companies

Editas Medicine & 41 more

View Biopure's full profile

Biopure has raised a total funding of $51.6M over 8 rounds. Its first funding round was on Dec 02, 1997. Its latest funding round was a Post IPO round on Nov 06, 2013 for $*****. 1 investor participated in its latest round. Biopure has 6 institutional investors.

Here is the list of recent funding rounds of Biopure:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 06, 2013	9198993	Post IPO	9833107	8090312	8451193	1312584
Jun 16, 2009	6133694	Grant (prize money)	2247790	5632790	8801706	Military Health
Sep 14, 2004	7877969	Post IPO	8812250	2664729	8988599	1453227

Access funding benchmarks and valuations. Sign up today!

View details of Biopure's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Biopure include Editas Medicine, LogicBio and Kedrion. Here is the list of Top 10 competitors of Biopure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Editas Medicine 2013, Cambridge (United States), Public	Developer of therapeutics for rare genetic diseases	$210M	Fidelity Investments, Deerfield & 21 others	63/100
2nd	LogicBio 2013, Lexington (United States), Acquired	Developer of viral vectors for the treatment of genetic and infectious diseases	$49M	Arix Bioscience, Orbimed & 5 others	60/100
3rd	Kedrion 2001, Barga (Italy), Acquired	Developer of plasma-derived products for hemophilia and immune system deficiencies	$189M	CDP Equity, Ampersand Capital & 4 others	60/100
4th	GBT 2011, San Francisco (United States), Acquired	Developer of small molecules for the treatment of sickle cell disease	$88.7M	Wellington, RA Capital Management & 8 others	58/100
5th	Cyclerion 2018, Cambridge (United States), Public	Developer of therapies for treating sickle cell disease and diabetic nephropathy	-	Lincoln Park Capital, Invus & 6 others	58/100
6th	Octapharma 1983, Lachen (Switzerland), Unfunded	Developer of plasma derived therapeutics for multiple diseases	-	-	54/100
7th	Modus Therapeutics 2011, Stockholm (Sweden), Series B	Developers of polysaccharide based drug for the treatment of Sickle Cell Disease	$22.9M	Healthcap, The Foundation for Baltic and East European Studies ... & 4 others	53/100
8th	Imara 2016, Cambridge (United States), Public	Small molecules to treat rare blood diseases such as sickle cell disease	$94M	Orbimed, Bay City Capital & 7 others	51/100
9th	Sierra Oncology 2003, Vancouver (Canada), Acquired	Developer of targeted therapies to treat cancer	$75M	Vivo Capital, Adams Street Partners & 18 others	51/100
10th	Emmaus Medical 2000, Torrance (United States), Acquired	Developer of small molecule therapeutics for the treatment of sickle cell anemia and sickle ß0-thalassemia	-	Mitsubishi UFJ Capital, E&Investment & 4 others	50/100
16th	Biopure 1984, United States, Deadpooled	Mold remediation, water damage restoration, and infectious disease control services	$51.6M	Oaktree Capital Management, Riverside Management Group ... & 4 others	33/100